US biotech bluebird bio (Nasdaq: BLUE) revealed that it had made mistakes in previous financial statements in a filing with the US Securities and Exchange Commission.
The filing details errors that were made in the annual report for 2022, and in the statements relating to the first three quarters of both 2022 and 2023.
bluebird has stated that it underestimated its lease assets and lease liabilities by between $100 million and $200 million in the annual report, and by a sum somewhere between $30 million and $125 million in each of the quarterly periods.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze